19677-69-1

Basic information

• Product Name: (4-ethoxypyridin-2-yl)Methanol
• Synonyms: (4-ethoxypyridin-2-yl)Methanol
• CAS NO: 19677-69-1
• Molecular Formula: C₈H₁₁NO₂
• Molecular Weight: 153.17844
• Mol File: 19677-69-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-ethoxypyridin-2-yl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-ethoxypyridin-2-yl)Methanol(19677-69-1)
• EPA Substance Registry System: (4-ethoxypyridin-2-yl)Methanol(19677-69-1)

Safety Data

• Hazardous Substances Data: 19677-69-1(Hazardous Substances Data)

Usage

Description

(4-ethoxypyridin-2-yl)Methanol, also known as EPM, is a pyridine derivative that serves as a versatile intermediate and building block in the synthesis of various compounds within the pharmaceutical and agrochemical industries. This colorless liquid has a molecular formula of C8H11NO2 and a molecular weight of 153.18 g/mol. Its significance in organic synthesis, especially in the preparation of heterocyclic compounds, is notable. Additionally, EPM has been investigated for its potential biological activities, such as anti-inflammatory and anti-cancer properties.

Uses

Used in Pharmaceutical Industry:
(4-ethoxypyridin-2-yl)Methanol is used as a chemical intermediate for the synthesis of pharmaceutical compounds, leveraging its reactivity and structural features to create a variety of medicinal agents.
Used in Agrochemical Industry:
EPM is utilized as a building block in the development of agrochemicals, contributing to the creation of products designed to enhance crop protection and yield.
Used in Organic Synthesis:
(4-ethoxypyridin-2-yl)Methanol is used as a reagent in organic synthesis, particularly for the preparation of heterocyclic compounds, which are integral in the formation of complex organic molecules.
Used in Biological Research:
EPM is employed as a subject of study in biological research, exploring its potential anti-inflammatory and anti-cancer properties for possible therapeutic applications.

Upstream product

• 98197-88-7 4-nitro-2-(hydroxymethyl)pyridine 
• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 
• 14474-56-7 4-ethoxypyridine-N-oxide 
• 77-78-1 dimethyl sulfate 
• 109-06-8 α-picoline 
• 5470-66-6 2-methyl-4-nitropyridine N-oxide 
• 931-19-1 2-methylpyridine N-oxide 
• 26883-31-8 4-ethoxy-2-methyl-pyridine-1-oxide 

Downstream Products

• 159996-13-1 2-(chloromethyl)-4-ethoxypyridine 
• 16665-43-3 4-ethoxypicolinaldehyde 

Relevant articles and documents

ANALOGS OF 2-PRALIDOXIME AS ANTIDOTES AGAINST ORGANOPHOSPHORUS NERVE AGENTS

Provided herein are compounds useful in treating exposure to an organophosphorus compound, such as a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, such as sarin. Compositions, e.g. pharmaceutical compositions or dosage forms, comprising the compounds also are provided herein. Methods of treating a patient exposed to a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, e.g., an organophosphorus compound, such as sarin, also are provided.

Design and synthesis of N-Aryl isothioureas as a novel class of gastric H+/K+-ATPase inhibitors

To find new H+/K+-ATPase inhibitors for the treatment of peptic ulcer disease, a series of novel N-aryl isothiourea derivatives were synthesized and their structures were identified by 1H NMR and GC-MS. The effects of these compounds on inhibiting gastric acid secretion were evaluated by the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. The results showed that, of the 37 N-aryl isothiourea compounds synthesized, 20 compounds have comparable or stronger gastric acid inhibitory activities than that of pantoprazole magnesium. The quantitative structure-activity relationships (QSARs) of the N-aryl isothiourea compounds were also studied by comparative molecular field analysis (CoMFA) computation, and the model structure that was supposed to give more powerful bioactivities was finally predicted. A series of novel N-aryl isothiourea derivatives were synthesized and evaluated for their effects of inhibiting gastric acid secretion using the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. Compounds 2c, 2e, and 2k have higher bioactivity. The quantitative structure-activity relationships also defined these structural requirements.

BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE

The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.